Utilizing induced neural stem cell-based delivery of a cytokine cocktail to enhance chimeric antigen receptor-modified T-cell therapy for brain cancer.

"CONFLICT OF INTEREST STATEMENT Shawn D. Hingtgen has an ownership interest in Falcon Therapeutics, Inc., which has licensed aspects of iNSC technology from UNC‐CH. All remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The UNC Flow Cytometry Core Facility is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center. Histopathology/Digital Pathology was performed by the Pathology Services Core at the University of North Carolina at Chapel Hill (UNC‐CH), which is supported in part by an NCI Center Core Support Grant (5P30CA016080‐42). Animal studies were performed within the UNC Lineberger Animal Services Core, which is supported in part by an NCI Center Core Support Grant (CA16086) to the UNC Lineberger Comprehensive Cancer Center. Research reported in this publication was supported by the Center for AIDS Research (5P30AI050410) and by funding from the National Institutes of Health (Program in Translational Medicine T32 GM122741 to UNC/ASW) and Accelerate Brain Cancer Cures."